Stocktoria
Cartesian Therapeutics, Inc. RNAC
Cartesian Therapeutics, Inc. (RNAC) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $2.8M at a -4658.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.386 |
| Retained earnings / assets | -2.774 |
| EBIT / assets | -0.484 |
| Equity / liabilities | -0.299 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| RNAC | Cartesian Therapeutics, Inc. | 1/9 | -10.08 | — | -92.8% |
| ONTX | Traws Pharma, Inc. | 3/9 | — | 1.4 | — |
| UPB | Upstream Bio, Inc. | 2/9 | — | — | — |
| XBIO | Xenetic Biosciences, Inc. | 3/9 | — | — | — |
| TXMD | TherapeuticsMD, Inc. | 5/9 | — | — | — |
| GOVX | GeoVax Labs, Inc. | 1/9 | — | — | — |
| CAMP | Camp4 Therapeutics Corp | 3/9 | -4.88 | — | — |
About Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
FAQ
Is RNAC financially healthy?
Cartesian Therapeutics, Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does RNAC pay a dividend?
No, Cartesian Therapeutics, Inc. does not currently pay a dividend.
How profitable is RNAC?
In FY2025, Cartesian Therapeutics, Inc. had a net margin of -4658.6%.
What is the analyst price target for RNAC?
The average Wall-Street price target for Cartesian Therapeutics, Inc. is $34.57, about 298.5% above the recent price, from 7 analysts.
Is RNAC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Cartesian Therapeutics, Inc.: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.